Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab Safety Study in Japanese Patients with IPF
NCT02036580Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2014
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tralokinumab in idiopathic pulmonary fibrosis (IPF), sponsored by AstraZeneca. Started Jan 2014; status: completed.
02
Drugs
tralokinumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02036580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036580.